TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.

José Á García-Sáenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.